Marko Anderluh

University of Ljubljana

H指数:28

被引数:2,785

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sulfonylurea Bioisosteres of Sulfonic Acid in JFD 00458-Based ST6GAL1 Inhibitors Enhance Membrane Permeability

磺酸类取代的磺酰脲生物电子等排体在JFD 00458基ST6GAL1抑制剂中增强膜通透性

ChemMedChem

IF3.4

2026-09-080

OAAI

β-1,4-galactosyltransferase 1 inhibitors modulate cellular N-glycan profiles

β-1,4-半乳糖基转移酶1抑制剂调控细胞N-糖基谱

Biotechnology Progress

IF2.5

2026-05-210

A nonavalent BODIPY with a multivalent arrangement of α-mannosides enables lectins recognition in fluorescence-based assays

一种九价BODIPY，其α-甘露糖苷的多价排列能够在荧光测定中实现凝集素识别

RSC Chem. Biol.

IF0

2025-12-060

OAAI

OSMI-4-based PROTACs do not influence O-GlcNAc transferase and O-GlcNAcylation levels in cells

基于OSMI-4的PROTACs不会影响细胞中O-GlcNAc转移酶和O-GlcNAc糖基化水平。

RSC Adv.

IF4.6

2025-07-280

Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis

DPP-4抑制剂有益效应的机制：作为预防/治疗心血管-脑血管稳态失调的有前景的视角

Frontiers in Pharmacology

IF4.8

2025-07-230

Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction (vol 8, 59, 2025)

Galectin-8 N末端域的纳摩尔级抑制剂的结合是通过非经典阳离子-π相互作用实现的（卷8，59，2025）

COMMUNICATIONS CHEMISTRY

IF6.2

2025-04-010

Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction

COMMUNICATIONS CHEMISTRY

IF6.2

2025-02-240

OAAI

New Inhibitors of β-1,4-Galactosyltransferase I Discovered by Virtual Screening

CHEMMEDCHEM

IF3.4

2025-01-120

PRE

Structural Aspects of Mycobacterium tuberculosis DNA Gyrase Targeted by Novel Bacterial Topoisomerase Inhibitors

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2024-11-221

PRE

Enhancing Antibacterial Efficacy: Combining Novel Bacterial Topoisomerase Inhibitors with Efflux Pump Inhibitors and Other Agents Against Gram-Negative Bacteria

增强抗菌功效: 将新型细菌拓扑异构酶抑制剂与外排泵抑制剂和其他针对革兰氏阴性细菌的药物相结合

ANTIBIOTICS-BASEL

IF4.6

2024-11-130

Targeting N-Acetylglucosaminidase in Staphylococcus aureus with Iminosugar Inhibitors

ANTIBIOTICS-BASEL

IF4.6

2024-08-100

Galectin-8N-Selective 4-Halophenylphthalazinone-Galactals Double π-Stack in a Unique Pocket

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2024-07-221

OAAI

Galectin-8 inhibition and functions in immune response and tumor biology

MEDICINAL RESEARCH REVIEWS

IF11.6

2024-04-130

OAAI

The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: From early hits to in vivo active antibacterials

在学术环境中有效对抗多重耐药细菌的新型细菌拓扑异构酶抑制剂的开发概述: 从早期命中到体内活性抗菌药物

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2024-01-014

Exploring Alternative Pathways to Target Bacterial Type II Topoisomerases Using NBTI Antibacterials: Beyond Halogen-Bonding Interactions

ANTIBIOTICS-BASEL

IF4.6

2023-05-184

Design of OSMI-4 Analogs Using Scaffold Hopping: Investigating the Importance of the Uridine Mimic in the Binding of OGT Inhibitors

CHEMMEDCHEM

IF3.4

2023-03-022

Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2023-03-019

OAAI

The Structural Features of Novel Bacterial Topoisomerase InhibitorsThat Define Their Activity on Topoisomerase IV

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-05-0323

OAAI

Discovery of a New Drug-like Series of OGT Inhibitors by Virtual Screening

MOLECULES

IF4.6

2022-03-195

OAAI

Repurposing of 8-Hydroxyquinoline-Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors

CHEMMEDCHEM

IF3.4

2022-02-038

PRE

Marko Anderluh

个人简介

教育背景

工作经历

荣誉奖项

研究方向